Який препарат з групи похідних сульфанілсечовини додати до метформіну?

Т. Ю. Юзвенко; К. О. Зуєв; Д. Г. Когут

doi:10.24026/1818-1384.4(41).2012.86139

Автор(и)

Т. Ю. Юзвенко Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ, Україна
К. О. Зуєв Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ, Україна
Д. Г. Когут Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ, Україна

DOI:

https://doi.org/10.24026/1818-1384.4(41).2012.86139

Ключові слова:

diabetes mellitus type 2, treatment, metformin, glimepiride

Анотація

Current views on combination therapy of diabetes mellitus type 2 on the basis of analysis of the results of large multicenter studies are discussed in a lecture.

Біографії авторів

Т. Ю. Юзвенко, Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ

T. Yuzvenko

К. О. Зуєв, Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ

K. Zuev

Д. Г. Когут, Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ

D. Kogut

Посилання

Stratton I.M., Adler A.I., Neil H.A.et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study // BMJ. – 2000. – Vol. 321. – P. 405-412. https://doi.org/10.1136/bmj.321.7258.405

Kahn S.E., Haffner S.M., Heise M.A. et al. for the ADOPT Study Group. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy // N. Engl. J. Med. – 2006. – Vol. 355. – P. 2427-2443. https://doi.org/10.1056/nejmoa066224

U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease // Diabetes. – 1995. – Vol. 44. – P. 1249-1258. https://doi.org/10.2337/diab.44.11.1249

Inzucchi S.E., Bergenstahl R.M., Buse J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach // Diabetes Care. – 2012. – Vol. 35(6). – P. 1364-1379. https://doi.org/10.2337/dc12-0413

IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes // International Diabetes Federation, Brussels. – 2005.

Type 2 diabetes: the management of type 2 diabetes: NICE Clinical Guideline 87: National Institute for Health and Clinical Excellence. – NICE. – 2009.

Rodbard H.W., Jellinger P.S., Davidson J.A. et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control // Endocr. Pract. – 2009. – Vol. 15. – P. 540-559. https://doi.org/10.4158/ep.15.6.540

American Diabetes Association. Position statement. Standards of Medical Care in Diabetes-2012 // Diabetes Care. – 2012. – Vol. 35 (Suppl. 1). – P. S11-S63. https://doi.org/10.2337/dc12-s011

Bailey C.J., Turner R.C. Metformin // N. Engl. J. Med. – 1996. – Vol. 334. – P. 574-579. https://doi.org/10.1056/nejm199602293340906

Lamanna C., Monami M., Marchionni N., Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials // Diabetes Obes. Metab. – 2011. – Vol. 13. – P. 221-228. https://doi.org/10.1111/j.1463-1326.2010.01349.x

Johnson A.B., Webster J.M., Sum C.F. et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type-II diabetic patients / / Metabolism. – 1993. – Vol. 42. – P. 1217-1222. https://doi.org/10.1016/0026-0495(93)90284-u

Зуев К. А. Метморфин как средство снижения веса // Международный эндокринологический журнал. – 2007. – №5(11). – C. 25-28.

Riccio A., Del Prato S., Vigili de Kreutzenberg S. et al. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin // Diabet. Metab. – 1991. – Vol. 17(Suppl. 1). – P. 180-184.

De Caterina R., Marchetti P. et al. The direct effects of metformin on platelet function in vitro // Eur. J. Clin. Pharmacol. – 1989. – Vol. 37(2). – P. 211-213. https://doi.org/10.1007/bf00558236

Beisswenger P., Ruggiero-Lopez D. Metformin inhibition of glycation processes // Diabetes Metab. – 2003. – Vol. 29(4 Pt 2). – P. 95-103. https://doi.org/10.1016/s1262-3636(03)72793-1

United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy // Ann. Intern. Med. – 1998. – Vol. 128. – P. 165-175. https://doi.org/10.7326/0003-4819-128-3-199802010-00001

Green B.D., Irwin N. et al. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 // European Journal of Pharmacology. – 2006. – Vol. 547. – P. 192-199. https://doi.org/10.1016/j.ejphar.2006.07.043

The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. – 2008. – Vol. 358. – P. 2560-2572. https://doi.org/10.1056/nejmoa0802987

Zoungas S., Heerspink L. et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial // oral presentation presented at EASD 2011.

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. – 2008. – Vol. 358. – P. 2545-2559. https://doi.org/10.1056/nejmoa0802743

Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes // N. Engl. J. Med. – 2007. – Vol. 356. – P. 2457-2471. https://doi.org/10.1056/nejmoa072761

Loke Y.K., Kwok C.S. et al. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies // BMJ. – 2011. – Vol. 342. – P. D1309. https://doi.org/10.1136/bmj.d1309

Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes // N. Engl. J. Med. – 2009. – Vol. 360. – P. 129-139. https://doi.org/10.1056/nejmoa0808431

Ismail-Beigi F., Moghissi E. et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials // Ann. Intern. Med. – 2011. – Vol. 154. – P. 554-559. https://doi.org/10.7326/0003-4819-154-8-201104190-00007

Monami M., Marchionni N. et al. Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease // International Journal of Cardiology. – 2008. – Vol. 126. – P. 247-251. https://doi.org/10.1016/j.ijcard.2007.03.135

Takada Y., Takata Y. et al. Effect of glimepiride (HOE 490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse // Europ. J. Pharmacol. – 1996. – Vol. 308. – P. 205-210. https://doi.org/10.1016/0014-2999(96)00288-9

Maloff B.L., Lockwood D.H. In vitro effects of a sulfonylurea on insulin action in adipocytes // J. Clin. Invest. – 1981. – Vol. 68. – P. 85-90. https://doi.org/10.1172/jci110257

Muller G., Satoh Y. et al. Extrapancreatic effects of sulfonylureas — a comparison between glimepiride and conventional sulfonylureas // Diabetes Res. Clin. Pract. – 1995. – Vol. 28. – P. 115-137. https://doi.org/10.1016/0168-8227(95)01089-v

Muller G., Wied S. The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro // Diabetes. – 1993. – Vol. 42(12). – P. 1852-1867. https://doi.org/10.2337/diab.42.12.1852

Bermudez V., Bermudez F. et al. Metformin plus low glimepiride doses improve significantly HOMAIR and HOMA?CELL without hyperinsulinemia in patients with type 2 diabetes // Arch. venez. farmacol. ter. – 2005. – Vol. 24(2). – P. 113-120.

Ueba H., Kuroki M. et al. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway // Atherosclerosis. – 2005. – Vol. 183(1). – P. 35-39. https://doi.org/10.1016/j.atherosclerosis.2005.01.055

Jojima T., Suzuki K. et al. Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway // Diabetes Obes. Metab. – 2009. – Vol.11(2). – P. 143-149. https://doi.org/10.1111/j.1463-1326.2008.00923.x

Shakuto S., Oshima K., Tsuchiya E. Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits // Atherosclerosis. – 2005. – Vol. 182(2). – P. 209-217. https://doi.org/10.1016/j.atherosclerosis.2005.01.044

Shimpi R.D., Patil P.H. et al. Comparison of effect of metformin in combination with glimepiride and glibenclamide on glycaemic control in patient with type 2 diabetes mellitus // International Journal of Pharm. Tech. Research. – 2009. – Vol. 1. – P. 50-61.

Colwell J.A. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus // Am. J. Cardiovasc. Drugs. – 2004. – Vol. 4(2). – P. 87-106. https://doi.org/10.2165/00129784-200404020-00003

Ozaki Y., Yatomi Y., Kume S. Effects of oral hypoglycaemic agents on platelet functions // Biochem. Pharmacol. – 1992. – Vol. 44(4). – P. 687-691. https://doi.org/10.1016/0006-2952(92)90404-7

Полторак В. В., Горбенко Н. И. Горшунская М. Ю. Блокада КАТФ-каналов препаратами сульфонилмочевины и кардиоваскулярная безопасность у больных сахарным диабетом II типа // Український медичний часопис. – 2002. – № 6(32). – С. 65-78.

Kouchi I., Murakami T. et al. KATP channels are common mediators of ischemic and calcium preconditioning in rabbits // Am. J. Physiol. – 1998. – Vol. 274. – P. 1106-1112. http://ajpheart.physiology.org/content/274/4/H1106

Zoungas S., Patel A. et al. Severe Hypoglycemia and Risks of Vascular Events and Death // N. Engl. J. Med. – 2010. – Vol. 363. – P. 1410-1418. https://doi.org/10.1056/nejmoa1003795

Gonzalez-Ortiz M. Guerrero-Romero J. et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus // J. of Diabetes and its complicftions. – 2009. – Vol. 23 (Issue 6). – P. 376-379. https://doi.org/10.1016/j.jdiacomp.2008.09.002